99 results
PRE 14A
ELVN
Enliven Therapeutics Inc
15 Apr 24
Preliminary proxy
4:05pm
market value, whether or not the award is subject to forfeiture provisions or restrictions on transfer, the nature of the property to be received … the size of the transaction, the overall financial position of the director, executive officer or related person, the direct or indirect nature
8-K
EX-99.1
ELVN
Enliven Therapeutics Inc
11 Apr 24
Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
8:02am
. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include
D
ELVN
Enliven Therapeutics Inc
3 Apr 24
$90.00 mm in equity / options / securities to be acquired, sold $90.00 mm, 20 investors
5:07pm
are "covered securities" for purposes
of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States
8-K
EX-10.1
ELVN
Enliven Therapeutics Inc
19 Mar 24
Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates
8:46am
the parties hereto with regard to the subjects hereof and thereof.
10.11 Independent Nature of Purchasers’ Obligations and Rights. The obligations of each
8-K
EX-99.1
76xc3c25rpqlb2
19 Mar 24
Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates
8:46am
8-K
v1rwrbp 53oj6l
19 Mar 24
Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates
8:46am
8-K
EX-99.1
uscai479of 28
14 Mar 24
Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
4:10pm
8-K
EX-99.1
lj676tn 5ji
9 Nov 23
Enliven Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
4:10pm
8-K
EX-99.1
ivndci
10 Aug 23
Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
4:10pm
424B5
fruzndy 0gmwasjuriz
6 Jul 23
Prospectus supplement for primary offering
4:06pm
8-K
EX-99.1
9sgg6v3o7tn 35x
23 Jun 23
Financial Statements and Supplementary Data
4:03pm
8-K
EX-99.2
x5ozfc33ehq rrj2z
23 Jun 23
Financial Statements and Supplementary Data
4:03pm